Nasus Pharma Ltd
NSRX · Pharmaceutical Preparations · EDGAR filings ↗
Reference price $3.10 — last insider purchase, 2026-06-17 (estimated from the dated SEC Form 4 price — not a live quote)
Grade
D43Pre-revenue clinical-stage intranasal-drug developer with explicit going-concern doubt and roughly one quarter of cash runway.
Strengths
- Differentiated powder-based intranasal (PBI) platform with issued patents and a 505(b)(2) path for NS002
- Current/quick ratio ~2.2 (33rd pct) gives modest near-term cover post-IPO
Risks
- Going-concern doubt; cash runway ~1 quarter (7th pct) and cash only $1.2M (6th pct)
- All candidates Phase 2 or earlier, no IND yet for lead NS002, Phase 3 not until Q4 2026
- Identified material weakness in internal controls; accumulated deficit $18.5M
Notable findings
- Going concern1 Risks Related to Our Financial Position and Capital Requirements ● We have not generated revenues from our continued activities, have incurred significant losses since our inception and ant
- Net lossNet loss (net margin -0.5%)
- Cash burnNegative free cash flow (-4.9M)
- Material weakness● We have identified material weaknesses in our internal control over financial reporting
Key metrics
Operating margin
-0.4%
Net margin
-0.5%
Return on equity
-211.6%
Return on assets
-117.0%
Current ratio
2.2×
Free cash flow
-$5M
Tangible book value
$3M
Cash & investments
$1M
Cash runway
1q
Stock comp / revenue
0.0%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-17 | Teleman Dan Benjamin | Buy | 6.5K | $3.10 |
| 2026-04-22 | Teleman Dan Benjamin | Buy | 2.9K | $3.76 |
| 2026-03-31 | Teleman Dan Benjamin | Buy | 15K | $2.04 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06205134 ↗ | Comparative Bioavailability of Intranasal Epinephrine Anaphylaxis, Anaphylactic Reaction | PHASE1/PHASE2 | Completed | 2024-02-02 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-25 | 2025-12-31 | 0001493152-26-012559 ↗ |